Know Labs, Inc. (NYSE American: KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it is working on certain curative actions to regain compliance to maintain its listing and appeal the NYSE's determination to delist its common stock to the Listings Qualifications Panel of the Exchange. The company's stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its determination, announced today, that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the bid price falling under $.10.
Know Labs, Inc. (NYSE American: KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), is proud to announce the formation of its new business unit, Know Labs Technology Licensing, (KTL). Modeled after the successful Qualcomm Technology Licensing (QTL) framework, KTL will be dedicated to licensing Know Labs’ robust intellectual property (IP) portfolio to corporate partners, academic institutions and research organizations, fostering innovation and accelerating the adoption of RFDS platform technology across a broad range of industries and the academic and scientific ecosystem.
Know Labs, Inc. (NYSE American: KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of $300K before deducting placement agent fees and other estimated expenses payable by the Company.
Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that on December 10, 2024, it received notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American") that the Company's previously-submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, NYSE American granted the Company until March 27, 2026 (the "Plan Period"), to regain compliance with the continued listing standards.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology released this morning an overview of its Form 10-K annual report for its fiscal year ending September 30, 2024, and provided reassurance regarding its progress over the past year, its plans and the state of its financial stability in light of its auditor required going concern opinion.
Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern. See further discussion in Note 2 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended September 30, 2024.
Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2024.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology, announced today two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve, Ph.D. They are tasked with both furthering the development of the Company’s non-invasive diagnostic technology platform and building relationships with potential strategic partners.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive sensor technology, announced today that it has retained The Stanbridge Group to secure a strategic relationship with an automotive original equipment manufacturer to embed the Know Labs sensor technology in automobile steering wheels. In early preliminary tests, the Know Labs sensor demonstrated, in a laboratory setting, that it can non-invasively determine blood alcohol levels and the Company believes, in an automobile steering wheel, could prohibit an impaired individual from driving.
Know Labs, Inc. (NYSE American: KNW) (the “Company” or “Know Labs”), a leading developer of non-invasive diagnostics technology, announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated September 27, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’ equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced the publication of its peer-reviewed study in IEEE Sensors Journal titled, “Non-Invasive Blood Glucose Measurement Using RF Spectroscopy and a lightGBM AI Model.” IEEE Sensors is the leading scientific journal in the U.S. that focuses on the theory, design, fabrication and applications of sensing devices, with an emphasis on emerging sensor innovations.
Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced that it has entered into definitive agreements with certain investors to purchase 6,365,385 Units for an aggregate offering of $1.655 million at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from the Offering will total $1.655 million before deducting estimated Offering expenses payable by Know Labs.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters’ option to purchase 1,987,500 warrants (the "Offering"). The Company raised gross proceeds of $3.445 million less the underwriting discounts and commissions and estimated Offering expenses payable by Know Labs.
Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from the Offering will total $3.445 million before deducting the underwriting discounts and commissions and estimated Offering expenses payable by Know Labs.
Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its third quarter of the fiscal year 2024 ended on June 30, 2024, on August 14, 2024, beginning at 1:30 pm PT.
